JP2020531443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531443A5 JP2020531443A5 JP2020508498A JP2020508498A JP2020531443A5 JP 2020531443 A5 JP2020531443 A5 JP 2020531443A5 JP 2020508498 A JP2020508498 A JP 2020508498A JP 2020508498 A JP2020508498 A JP 2020508498A JP 2020531443 A5 JP2020531443 A5 JP 2020531443A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 119
- 150000003839 salts Chemical class 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 51
- 150000002431 hydrogen Chemical class 0.000 claims description 45
- -1 substituted Chemical class 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 208000007475 hemolytic anemia Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- 208000035185 Hemolytic Congenital Anemia Diseases 0.000 claims description 4
- 206010060893 Hereditary haemolytic anaemia Diseases 0.000 claims description 4
- 208000002903 Thalassemia Diseases 0.000 claims description 4
- 201000001516 congenital hemolytic anemia Diseases 0.000 claims description 4
- 208000024987 familial hemolytic anemia Diseases 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims description 3
- 206010014490 Elliptocytosis hereditary Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 208000001825 Hereditary elliptocytosis Diseases 0.000 claims description 2
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000005980 beta thalassemia Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000009601 hereditary spherocytosis Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 208000030760 Anaemia of chronic disease Diseases 0.000 claims 1
- 208000022400 anemia due to chronic disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 0 C*C(C1=O)=CC=NCC1(C)[Rn](C)C(C)N Chemical compound C*C(C1=O)=CC=NCC1(C)[Rn](C)C(C)N 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- RTINBBNUUQZXQW-AATRIKPKSA-N CC(N)[Rn](C)/C(/C)=C/N=C Chemical compound CC(N)[Rn](C)/C(/C)=C/N=C RTINBBNUUQZXQW-AATRIKPKSA-N 0.000 description 1
- JCGZIBQMKYESAK-UHFFFAOYSA-N CCCN(C=CC(C)(C=N1)[Rn](C)C)C1=O Chemical compound CCCN(C=CC(C)(C=N1)[Rn](C)C)C1=O JCGZIBQMKYESAK-UHFFFAOYSA-N 0.000 description 1
- WHXNOIJKJFYUSM-UHFFFAOYSA-N C[n](c1c2C=NN(Cc(nc(cc3)N)c3F)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 Chemical compound C[n](c1c2C=NN(Cc(nc(cc3)N)c3F)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 WHXNOIJKJFYUSM-UHFFFAOYSA-N 0.000 description 1
- FXZBMEYGWLGHNX-UHFFFAOYSA-N C[n](c1c2C=NN(Cc3c[s]nc3)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 Chemical compound C[n](c1c2C=NN(Cc3c[s]nc3)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 FXZBMEYGWLGHNX-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023005925A JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017097496 | 2017-08-15 | ||
| CNPCT/CN2017/097496 | 2017-08-15 | ||
| US201862673533P | 2018-05-18 | 2018-05-18 | |
| US201862673526P | 2018-05-18 | 2018-05-18 | |
| US62/673,526 | 2018-05-18 | ||
| US62/673,533 | 2018-05-18 | ||
| PCT/US2018/000128 WO2019035864A1 (en) | 2017-08-15 | 2018-08-15 | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023005925A Division JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531443A JP2020531443A (ja) | 2020-11-05 |
| JP2020531443A5 true JP2020531443A5 (enExample) | 2021-09-30 |
| JP7275107B2 JP7275107B2 (ja) | 2023-05-17 |
Family
ID=63524352
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508498A Active JP7275107B2 (ja) | 2017-08-15 | 2018-08-15 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2020508455A Active JP7301040B2 (ja) | 2017-08-15 | 2018-08-15 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2022199462A Pending JP2023027276A (ja) | 2017-08-15 | 2022-12-14 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2023005925A Active JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A Pending JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508455A Active JP7301040B2 (ja) | 2017-08-15 | 2018-08-15 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2022199462A Pending JP2023027276A (ja) | 2017-08-15 | 2022-12-14 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2023005925A Active JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A Pending JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Country Status (34)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
| MX2020001832A (es) * | 2017-08-15 | 2020-07-22 | Agios Pharmaceuticals Inc | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. |
| WO2019079541A1 (en) | 2017-10-20 | 2019-04-25 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| BR112021015996A2 (pt) * | 2019-02-13 | 2021-11-09 | Agios Pharmaceuticals Inc | Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes |
| TWI856118B (zh) * | 2019-06-26 | 2024-09-21 | 日商日產化學股份有限公司 | 電荷輸送性塗料 |
| EP4031132A4 (en) | 2019-09-19 | 2023-09-13 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| WO2022020424A1 (en) * | 2020-07-21 | 2022-01-27 | The Regents Of The University Of Michigan | Compositions and methods for activating pyruvate kinase |
| CN112490502B (zh) * | 2020-12-04 | 2022-01-21 | 广州天赐高新材料股份有限公司 | 一种电解液及锂二次电池 |
| TW202245758A (zh) | 2021-02-08 | 2022-12-01 | 美商全球血液治療公司 | 作為丙酮酸激酶活化劑之吡咯啶-吡唑 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US20240409542A1 (en) * | 2021-09-30 | 2024-12-12 | Sitryx Therapeutics Limited | Novel compounds |
| EP4433057A1 (en) * | 2021-11-16 | 2024-09-25 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
| CN116159061A (zh) * | 2023-03-09 | 2023-05-26 | 上海市第十人民医院 | 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用 |
| CN121175238A (zh) | 2023-03-28 | 2025-12-19 | 本田技研工业株式会社 | 信息提供方法、信息提供程序、存储介质及信息处理装置 |
| AU2024271856A1 (en) | 2023-05-15 | 2025-11-27 | Agios Pharmaceuticals, Inc. | Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one |
| WO2025010390A1 (en) * | 2023-07-05 | 2025-01-09 | Agios Pharmaceuticals, Inc. | Synthesis of pyruvate kinase activators |
| WO2025207563A1 (en) | 2024-03-27 | 2025-10-02 | Agios Pharmaceuticals, Inc. | Use of a pk activator in the treatment of sickle cell disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405635A (en) | 1979-06-18 | 1983-09-20 | Merrell Dow Pharmaceuticals Inc. | 4-Aroylimidazol-2-ones and their use as pharmaceuticals |
| US4883914A (en) | 1987-08-17 | 1989-11-28 | American Cyanamid Company | Benzenesulfonyl carboxamide compounds useful as herbicidal agents |
| IL147757A0 (en) | 1999-07-30 | 2002-08-14 | Abbott Gmbh & Co Kg | 2-pyrazolin-5-ones |
| MXPA02002319A (es) | 1999-09-04 | 2002-07-30 | Astrazeneca Ab | Derivados 2-hidroxi-2-metil-3,3,3-trifluoropropanamida con n-fenilo susbtituido que elevan la actividad de la deshidrogenasa de piruvato. |
| EP1972629A1 (en) * | 2007-03-23 | 2008-09-24 | Mutabilis SA | New imidazolo-heteroaryl derivatives with antibacterial properties |
| FR2933983B1 (fr) * | 2008-07-15 | 2010-08-27 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| JP2011529066A (ja) * | 2008-07-23 | 2011-12-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | 三環式ピラゾロピリジンキナーゼ阻害剤 |
| EP2334673A1 (en) * | 2008-08-29 | 2011-06-22 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| EP2344453B1 (en) | 2008-10-09 | 2016-12-28 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
| CN102448951B (zh) * | 2009-04-06 | 2017-05-10 | 安吉奥斯医药品有限公司 | 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法 |
| PT2448582T (pt) | 2009-06-29 | 2017-07-10 | Agios Pharmaceuticals Inc | Compostos e composições terapêuticas |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| EA023796B1 (ru) | 2010-12-06 | 2016-07-29 | Глэксо Груп Лимитед | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| CN108451955B (zh) | 2011-05-03 | 2022-02-01 | 安吉奥斯医药品有限公司 | 用于治疗的丙酮酸激酶活化剂 |
| WO2012151452A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use in therapy |
| EP3372230B1 (en) | 2011-05-03 | 2020-08-12 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| WO2012151448A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
| WO2013012915A1 (en) * | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US20140249150A1 (en) * | 2011-10-13 | 2014-09-04 | Agios Pharmaceuticals, Inc | Activators of pyruvate kinase m2 and methods of treating disease |
| WO2014018851A1 (en) | 2012-07-26 | 2014-01-30 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| US9458132B2 (en) | 2012-11-08 | 2016-10-04 | Agios Pharmaceuticals, Inc | Therapeutic compounds and compositions and their use as PKM2 modulators |
| JP2016506943A (ja) * | 2013-01-30 | 2016-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｍｋｎｋ−１キナーゼ阻害剤としてのアミドイミダゾピリダジン類 |
| EP2968323A4 (en) | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| LT3661925T (lt) | 2017-07-07 | 2022-03-10 | Inflazome Limited | Naujieji sulfonamido karboksamido junginiai |
| CA3071150A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| SG11202001182QA (en) | 2017-08-15 | 2020-03-30 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
| MX2020001832A (es) | 2017-08-15 | 2020-07-22 | Agios Pharmaceuticals Inc | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. |
| AR112475A1 (es) | 2017-08-15 | 2019-10-30 | Agios Pharmaceuticals Inc | Moduladores de piruvato quinasas y uso de los mismos |
| BR112021015996A2 (pt) * | 2019-02-13 | 2021-11-09 | Agios Pharmaceuticals Inc | Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes |
-
2018
- 2018-08-15 MX MX2020001832A patent/MX2020001832A/es unknown
- 2018-08-15 JP JP2020508498A patent/JP7275107B2/ja active Active
- 2018-08-15 CR CR20200123A patent/CR20200123A/es unknown
- 2018-08-15 ES ES18766063T patent/ES2966825T3/es active Active
- 2018-08-15 US US16/639,081 patent/US11590132B2/en active Active
- 2018-08-15 RS RS20220003A patent/RS62871B1/sr unknown
- 2018-08-15 PL PL18766400.8T patent/PL3668512T3/pl unknown
- 2018-08-15 UA UAA202001747A patent/UA126292C2/uk unknown
- 2018-08-15 PT PT187664008T patent/PT3668512T/pt unknown
- 2018-08-15 AU AU2018316588A patent/AU2018316588B2/en active Active
- 2018-08-15 KR KR1020237028222A patent/KR102764124B1/ko active Active
- 2018-08-15 WO PCT/US2018/000128 patent/WO2019035864A1/en not_active Ceased
- 2018-08-15 WO PCT/US2018/000127 patent/WO2019035863A1/en not_active Ceased
- 2018-08-15 SM SM20220023T patent/SMT202200023T1/it unknown
- 2018-08-15 MD MDE20200663T patent/MD3668513T2/ro unknown
- 2018-08-15 EP EP18766400.8A patent/EP3668512B1/en active Active
- 2018-08-15 CA CA3072455A patent/CA3072455A1/en active Pending
- 2018-08-15 CN CN201880053315.9A patent/CN111032045B/zh active Active
- 2018-08-15 FI FIEP18766400.8T patent/FI3668512T3/fi active
- 2018-08-15 RS RS20230354A patent/RS64221B1/sr unknown
- 2018-08-15 KR KR1020207007344A patent/KR102717594B1/ko active Active
- 2018-08-15 DK DK18766400.8T patent/DK3668512T3/da active
- 2018-08-15 TW TW111135803A patent/TWI823580B/zh active
- 2018-08-15 MY MYPI2020000757A patent/MY204421A/en unknown
- 2018-08-15 KR KR1020207007346A patent/KR102642408B1/ko active Active
- 2018-08-15 SG SG11202001353PA patent/SG11202001353PA/en unknown
- 2018-08-15 WO PCT/US2018/000129 patent/WO2019035865A1/en not_active Ceased
- 2018-08-15 LT LTEPPCT/US2018/000129T patent/LT3668512T/lt unknown
- 2018-08-15 SI SI201830558T patent/SI3668513T1/sl unknown
- 2018-08-15 MX MX2020001833A patent/MX2020001833A/es unknown
- 2018-08-15 ES ES18766400T patent/ES2944545T3/es active Active
- 2018-08-15 SG SG11202001262QA patent/SG11202001262QA/en unknown
- 2018-08-15 JP JP2020508455A patent/JP7301040B2/ja active Active
- 2018-08-15 TW TW107128429A patent/TWI790271B/zh active
- 2018-08-15 BR BR112020003254-9A patent/BR112020003254A2/pt unknown
- 2018-08-15 CN CN201880053325.2A patent/CN111032046B/zh active Active
- 2018-08-15 ES ES18779068T patent/ES2905100T3/es active Active
- 2018-08-15 EP EP18779068.8A patent/EP3668513B1/en active Active
- 2018-08-15 SI SI201830914T patent/SI3668512T1/sl unknown
- 2018-08-15 US US16/639,086 patent/US11464775B2/en active Active
- 2018-08-15 BR BR112020003262-0A patent/BR112020003262A2/pt active Search and Examination
- 2018-08-15 EP EP18766063.4A patent/EP3668881B1/en active Active
- 2018-08-15 HR HRP20220039TT patent/HRP20220039T1/hr unknown
- 2018-08-15 PT PT187790688T patent/PT3668513T/pt unknown
- 2018-08-15 CN CN202310962497.4A patent/CN117186119A/zh active Pending
- 2018-08-15 IL IL272599A patent/IL272599B/en unknown
- 2018-08-15 EP EP21207073.4A patent/EP4026838A1/en not_active Withdrawn
- 2018-08-15 DK DK18779068.8T patent/DK3668513T3/da active
- 2018-08-15 HU HUE18779068A patent/HUE057178T2/hu unknown
- 2018-08-15 HR HRP20230452TT patent/HRP20230452T1/hr unknown
- 2018-08-15 PL PL18779068T patent/PL3668513T3/pl unknown
- 2018-08-15 AU AU2018316587A patent/AU2018316587B2/en active Active
- 2018-08-15 PE PE2020000245A patent/PE20200724A1/es unknown
- 2018-08-15 PH PH1/2020/500343A patent/PH12020500343B1/en unknown
- 2018-08-15 HU HUE18766400A patent/HUE061910T2/hu unknown
- 2018-08-15 LT LTEPPCT/US2018/000128T patent/LT3668513T/lt unknown
- 2018-08-15 US US16/639,075 patent/US11364240B2/en active Active
- 2018-08-15 SM SM20230146T patent/SMT202300146T1/it unknown
- 2018-08-15 TW TW107128431A patent/TWI796353B/zh active
-
2020
- 2020-02-11 IL IL272597A patent/IL272597B/en unknown
- 2020-02-13 CL CL2020000375A patent/CL2020000375A1/es unknown
- 2020-03-12 CO CONC2020/0002961A patent/CO2020002961A2/es unknown
- 2020-03-12 CO CONC2020/0002959A patent/CO2020002959A2/es unknown
- 2020-03-13 EC ECSENADI202018487A patent/ECSP20018487A/es unknown
- 2020-11-19 US US16/952,257 patent/US11040036B2/en active Active
-
2022
- 2022-01-18 CY CY20221100039T patent/CY1124953T1/el unknown
- 2022-01-27 US US17/586,777 patent/US11872225B2/en active Active
- 2022-04-26 IL IL292530A patent/IL292530B2/en unknown
- 2022-05-16 US US17/744,806 patent/US11957680B2/en active Active
- 2022-12-14 JP JP2022199462A patent/JP2023027276A/ja active Pending
-
2023
- 2023-01-18 JP JP2023005925A patent/JP7530453B2/ja active Active
- 2023-01-20 US US18/099,311 patent/US12133853B2/en active Active
- 2023-05-03 AU AU2023202772A patent/AU2023202772B2/en active Active
-
2024
- 2024-07-26 JP JP2024121066A patent/JP2024147805A/ja active Pending
- 2024-08-16 AU AU2024205818A patent/AU2024205818A1/en not_active Abandoned
- 2024-09-12 US US18/882,884 patent/US20250144093A1/en active Pending